Hologic, Inc. (NASDAQ: HOLX) is a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems, and surgical products dedicated to serving the healthcare needs of women throughout the world.
Historically, Hologic developed, manufactured, and marketed products focused on mammography, breast care, and osteoporosis assessment. In 2007, we expanded our focus and now provide a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, osteoporosis assessment, preterm birth risk assessment, mini C-arms for extremity imaging, and molecular diagnostic products including reagents for a variety of DNA and RNA analysis applications. We are proud of this achievement, and conscious of the responsibility that our leadership position brings with it. We believe that the health issues facing women today deserve and demand the singular dedication of a passionate company.
Our core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health.
Every year, Hologic spends tens of millions of dollars in research and development to advance the field of women’s healthcare. As our clinical areas expand, we are taking on a broader range of problems, but our goal is always the same: to deliver innovative technologies that result in better outcomes for women.
Hologic is committed to bringing our best-in-class healthcare products to women everywhere. Hologic has offices throughout Europe, in the UK, Germany, France, Belgium, Italy, and Spain, as well as in Australia and Canada. These operations have been established to handle sales, service, training and distribution to clinical laboratories. Hologic also utilizes a network of third-party dealers and distributors to offer a range of products throughout the world, including markets such as China, India, the Middle East, Mexico, South America and South Africa.
Learn more about Hologic, Inc.